Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Liu, Yang ^a   Quang, Phong ^a   Braggio, Esteban ^b   Ngo, Hai ^a   Badalian Very, Gayane ^a   Flores, Ludmila ^a   Zhang, Yong ^a   Sacco, Antonio ^a   Maiso, Patricia ^a   Azab, Abdel Kareem ^a   Azab, Feda ^a   Carrasco, Ruben ^a   Rollins, Barrett J ^a   Roccaro, Aldo M ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNA; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 11A; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 11B; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 18; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 19; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 21; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 8; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PATHOPHYSIOLOGY; PLASMA CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; MICE; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NF-KAPPA B; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84879062784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066982     Document Type: Article

References (38)

1. Hehlgans T, Pfeffer K, (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115: 1-20. doi:10.1111/j.1365-2567.2005.02143.x. PubMed: 15819693.
2. Cheng X, Kinosaki M, Murali R, Greene MI, (2003) The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res 27: 287-294. doi:10.1385/IR:27:2-3:287. PubMed: 12857975.
3. Kwon B, Kim BS, Cho HR, Park JE, Kwon BS, (2003) Involvement of tumor necrosis factor receptor superfamily(TNFRSF) members in the pathogenesis of inflammatory diseases. Exp Mol Med 35: 8-16. doi:10.1038/emm.2003.2. PubMed: 12642898.
4. Zhou T, Mountz JD, Kimberly RP, (2002) Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res 26: 323-336. doi:10.1385/IR:26:1-3:323. PubMed: 12403370.
5. Locksley RM, Killeen N, Lenardo MJ, (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501. doi:10.1016/S0092-8674(01)00237-9. PubMed: 11239407.
6. Silke J, Brink R, (2010) Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs. Cell Death Differ 17: 35-45. doi:10.1038/cdd.2009.114. PubMed: 19680262.
7. Tamada K, Chen L, (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55: 355-362. doi:10.1007/s00262-005-0081-y. PubMed: 16187084.
8. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, et al. (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101: 2762-2769. doi:10.1182/blood-2002-09-2813. PubMed: 12433678.
9. Shen X, Zhu W, Zhang X, Xu G, Ju S, (2011) A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol Cell Biochem 357: 21-30. doi:10.1007/s11010-011-0871-9. PubMed: 21607696.
10. Dimberg LY, Dimberg AI, Ivarsson K, Strömberg T, Osterborg A, et al. (2005) Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 106: 1346-1354. doi:10.1182/blood-2004-04-1322. PubMed: 15860671.
11. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S, (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142. doi:10.1038/ni759. PubMed: 11812990.
12. Vecchiarelli A, Pericolini E, Gabrielli E, Agostini M, Bistoni F, et al. (2009) The GITRL-GITR system alters TLR-4 expression on DC during fungal infection. Cell Immunol 257: 13-22. doi:10.1016/j.cellimm.2009.02.001. PubMed: 19272591.
13. Liu B, Li Z, Mahesh SP, Pantanelli S, Hwang FS, et al. (2008) Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem 283: 8202-8210. doi:10.1074/jbc.M708944200. PubMed: 18230609.
14. Hanabuchi S, Watanabe N, Wang YH, Ito T, Shaw J, et al. (2006) Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107: 3617-3623. doi:10.1182/blood-2005-08-3419. PubMed: 16397134.
15. Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, et al. (2007) Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 82: 93-105. doi:10.1189/jlb.0906568. PubMed: 17449724.
16. Demchenko YN, Kuehl WM, (2010) A critical role for the NFkB pathway in multiple myeloma. Oncotarget 1: 59-68. PubMed: 20890394.
17. Yang F, Tang E, Guan K, Wang CY, (2003) IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170: 5630-5635. PubMed: 12759443.
18. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, et al. (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99: 4079-4086. doi:10.1182/blood.V99.11.4079. PubMed: 12010810.
19. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, et al. (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66: 6675-6682. doi:10.1158/0008-5472.CAN-06-0190. PubMed: 16818641.
20. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472. doi:10.1038/nature09837. PubMed: 21430775.
21. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP, (2002) Role of GITR in activation response of T lymphocytes. Blood 100: 350-352. doi:10.1182/blood-2001-12-0276. PubMed: 12070049.
22. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 92: 5520-5524. doi:10.1073/pnas.92.12.5520. PubMed: 7777541.
23. Biegel JA, White PS, Marshall HN, Fujimori M, Zackai EH, et al. (1993) Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet 52: 176-182. PubMed: 8434586.
24. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, et al. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11: 6823-6834. doi:10.1158/1078-0432.CCR-05-0585. PubMed: 16203770.
25. Nomoto S, Haruki N, Tatematsu Y, Konishi H, Mitsudomi T, et al. (2000) Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer 28: 342-346. doi:10.1002/1098-2264(200007)28:3. PubMed: 10862041.
26. Poetsch M, Dittberner T, Woenckhaus C, (2002) Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Oncogene 21: 3038-3042. doi:10.1038/sj.onc.1205457. PubMed: 12082534.
27. Katzenberger T, Kalla J, Leich E, Stöcklein H, Hartmann E, et al. (2009) A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113: 1053-1061. PubMed: 18978208.
28. Schultheis B, Krämer A, Willer A, Hegenbart U, Goldschmidt H, et al. (1999) Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 13: 2099-2103. doi:10.1038/sj.leu.2401609. PubMed: 10602435.
29. Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ, et al. (2012) Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 26: 991-1000. doi:10.1038/leu.2011.313. PubMed: 22064350.
30. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, et al. (2007) Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 21: 2442-2454. doi:10.1096/fj.06-7724com. PubMed: 17360848.
31. Teodorovic LS, Riccardi C, Torres RM, Pelanda R, (2012) Murine B cell development and antibody responses to model antigens are not impaired in the absence of the TNF receptor GITR. PLOS ONE 7: e31632. doi:10.1371/journal.pone.0031632. PubMed: 22328941.
32. Rauert H, Stühmer T, Bargou R, Wajant H, Siegmund D, (2011) TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2: e194. doi:10.1038/cddis.2011.78. PubMed: 21850048.
33. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, et al. (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311-5321. doi:10.1158/1078-0432.CCR-11-0476. PubMed: 21724551.
34. Berenson JR, Ma HM, Vescio R, (2001) The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28: 626-633. doi:10.1053/sonc.2001.29542. PubMed: 11740821.
35. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, et al. (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115: 3541-3552. doi:10.1182/blood-2009-09-243535. PubMed: 20053756.
36. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130. doi:10.1016/j.ccr.2007.07.004. PubMed: 17692804.
37. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. doi:10.1016/j.ccr.2007.07.003. PubMed: 17692805.
38. Gilmore TD, (2007) Multiple myeloma: lusting for NF-kappaB. Cancer Cell 12: 95-97. doi:10.1016/j.ccr.2007.07.010. PubMed: 17692798.